Skip to main content

Bryan McMichael

Equibles does not estimate personal net worth.

Get an email with a short summary when Coherus Oncology, Inc. publishes a filing, an earnings call transcript or a press release.

Get CHRS alerts

About Bryan McMichael

Bryan McMichael is recorded as Chief Accounting Officer at Coherus Oncology, Inc. (CHRS) since September 7, 2022 and CFO at Coherus Oncology, Inc. (CHRS). The newest filing on record that lists Bryan McMichael as CFO at Coherus Oncology, Inc. (CHRS) is dated April 20, 2026. Coherus Oncology, Inc. reported in an 8-K filed August 8, 2024 that Bryan McMichael was appointed Chief Financial Officer, effective August 1, 2024. Coherus Oncology, Inc. reported in an 8-K filed December 11, 2023 that Bryan McMichael was appointed Interim Chief Financial Officer and Principal Financial Officer, effective December 8, 2023. Coherus Oncology, Inc. reported in an 8-K filed September 9, 2022 that Bryan McMichael was appointed Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer, effective September 7, 2022. Bryan McMichael has spoken on 8 earnings calls across 1 company, most recently for Coherus Oncology, Inc. on August 5, 2026. Coherus Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Coherus Oncology, Inc. includes Dennis Lanfear (CEO), McDavid Stilwell (CFO), Alan C. Mendelson (Board Member) and 7 others.

“On August 7, 2024, the Company’s board of directors appointed Bryan McMichael, age 46, the Company’s current Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, to serve as the Company’s Chief Financial Officer effective August 1, 2024.”
Coherus Oncology, Inc. Form 8-K, filed August 8, 2024 · Read the filing
“The Board of Directors of the Company appointed Bryan McMichael, age 45, to serve as the Company's Interim Chief Financial Officer and Principal Financial Officer effective December 8, 2023.”
Coherus Oncology, Inc. Form 8-K, filed December 11, 2023 · Read the filing

Bryan McMichael on recent calls

“Q2 2026 marked the one-year anniversary of the divestiture of the Eudenica franchise, which allowed us to decrease our secured and convertible debt by over 90%, as well as reduce our overarching cost structure and core cash burn rate as we refocused the business.”
CFO, Q2 2026 Coherus Oncology, Inc. Earnings Conference Call ·
“After over a year of deal activity, the third quarter of 2025 was the first complete quarter following our exit from the biosimilar business. We used the proceeds from the divestiture to eliminate all near-term debt, transitioning into a company focused solely on innovative oncology.”
CFO, Coherus Oncology, Inc. Q3 FY2025 Earnings Call ·
“Today, I will limit my discussion to key financial updates and refer you to our earnings press release for the second quarter and year-to-date 2025 figures and detailed results.”
CFO, Coherus Oncology, Inc. Q2 FY2025 Earnings Call ·
“Today, I will discuss the successful closing of the UDENYCA divestiture, which occurred at the beginning of Q2 and the related discontinued operations presentation reflected in Coherus' financial reporting.”
CFO, Coherus Oncology, Inc. Q1 FY2025 Earnings Call ·
“Today, I will cover the fourth quarter and annual results and provide an overview of Coherus’ transition culminating with the expected divestiture of UDENYCA, which sets the company up for focus and execution solely on oncology.”
CFO, Coherus Oncology, Inc. Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Coherus Oncology, Inc.

Recent activity